Article Details
Retrieved on: 2024-10-31 14:29:27
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details Kither Biotech's launch of a Phase 1 trial for KIT2014, an inhaled peptide therapy targeting Cystic Fibrosis (CF), complementing existing CFTR modulators. This aligns with the key concept 'Biotech' and tags reflecting CF treatments and racial considerations.
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here